Related Experiment Video

Updated: Aug 15, 2026

A Low Cost Setup for Behavioral Audiometry in Rodents
09:23

A Low Cost Setup for Behavioral Audiometry in Rodents

Published on: October 16, 2012

[Antiarrhythmic agents in tinnitus treatment]

T Lenarz

    Laryngologie, Rhinologie, Otologie
    |March 1, 1985
    PubMed

    Insights

    Intravenous lidocaine effectively suppressed tinnitus in over half of patients with sensorineural hearing loss. This treatment also showed measurable electrophysiological changes, suggesting a potential therapeutic mechanism for tinnitus management.

    Area of Science:

    • Otolaryngology
    • Neuroscience
    • Pharmacology

    Background:

    • Tinnitus treatment is challenging due to the lack of objective diagnostic parameters.
    • Rational tinnitus treatment requires objective assessment criteria.
    • Sensorineural hearing loss often presents with a well-defined tinnitus symptom.

    Purpose of the Study:

    • To evaluate the efficacy of intravenous lidocaine in managing tinnitus patients.
    • To assess the impact of lidocaine on subjective tinnitus perception.
    • To investigate electrophysiological changes associated with lidocaine treatment for tinnitus.

    Main Methods:

    • A randomized, blind-controlled, cross-over trial was conducted.
    • 20 patients with sensorineural hearing loss and tinnitus received intravenous lidocaine or saline.
    • Brainstem Evoked Response Audiometry (BERA) was used to monitor electrophysiological changes.

    Main Results:

    • 13 out of 20 patients reported over 50% tinnitus suppression with lidocaine.
    • No significant tinnitus suppression was observed with saline treatment.
    • Lidocaine administration resulted in reversible lengthening of central conduction time in BERA, without hearing impairment.

    Conclusions:

    • Intravenous lidocaine demonstrates significant potential for tinnitus suppression in patients with sensorineural hearing loss.
    • Lidocaine's therapeutic effect on tinnitus may be linked to electrophysiological alterations.
    • Further research into the mechanisms of lidocaine action in tinnitus is warranted.

    More Related Videos

    A Protocol for the Administration of Real-Time fMRI Neurofeedback Training07:05

    A Protocol for the Administration of Real-Time fMRI Neurofeedback Training

    Published on: August 24, 2017

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    Related Concept Videos

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Dysrhythmias II: Classification of Tachyarrhythmias01:28

    Dysrhythmias II: Classification of Tachyarrhythmias

    Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...